Is VUG a Good ETF to Buy?
For the last few years, earnings growth from the tech…
Sell
22
VKTX Quote, Financials, Valuation and Earnings
Last price:
$29.55
Seasonality move
:
2.26%
Day range:
$27.59 - $30.14
52-week range:
$24.41 - $89.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.38x
Volume:
7.6M
Avg. volume:
5M
1-year change:
-58.2%
Market cap:
$3B
Revenue:
--
EPS (TTM):
-$1.00
Analysts' Opinion
-
Consensus RatingViking Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $99.29, Viking Therapeutics has an estimated upside of 274.41% from its current price of $26.52.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $38.00 representing -43.29% downside risk from its current price of $26.52.
Fair Value
-
According to the consensus of 10 analysts, Viking Therapeutics has 274.41% upside to fair value with a price target of $99.29 per share.
VKTX vs. S&P 500
-
Over the past 5 trading days, Viking Therapeutics has underperformed the S&P 500 by -2.77% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Viking Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Viking Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Viking Therapeutics reported revenues of --.
Earnings Growth
-
Viking Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Viking Therapeutics reported earnings per share of -$0.32.
Enterprise value:
2.1B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-23.63x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$70.4M | -$100.8M | -$150.9M | -$29.3M | -$46.2M | |
| EBITDA | -$70.1M | -$100.5M | -$150.6M | -$29.2M | -$46.1M | |
| Diluted EPS | -$0.91 | -$0.92 | -$1.00 | -$0.25 | -$0.32 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $256.1M | $210.5M | $167M | $367.2M | $907.2M | |
| Total Assets | $256.5M | $210.7M | $168.5M | $368.5M | $908.3M | |
| Current Liabilities | $12.1M | $8.8M | $21.9M | $19.1M | $27.4M | |
| Total Liabilities | $12.2M | $8.8M | $23.2M | $20.1M | $28M | |
| Total Equity | $244.3M | $201.9M | $145.3M | $348.4M | $880.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$48.4M | -$73.4M | -$87.8M | -$17.6M | -$31.2M | |
| Cash From Investing | $54.8M | -$179.1M | -$553.4M | $35.7M | $6.6M | |
| Cash From Financing | $4.2M | $271.4M | $612.5M | $188K | $1M | |
| Free Cash Flow | -$48.4M | -$73.4M | -$87.8M | -$17.6M | -$31.2M | |
VKTX
Sector
Market Cap
$3B
$36.4M
Price % of 52-Week High
29.76%
45.1%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-58.2%
-39.83%
Beta (5-Year)
0.903
0.773
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$27.94
200-day SMA
Sell
Level
$52.16
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$29.45
Relative Strength Index (RSI14)
Sell
Level
48.08
ADX Line
Neutral
Level
0
Williams %R
Buy
Level
-82.3701
50-day SMA
Sell
Level
$33.83
MACD (12, 26)
Sell
Level
-1.86
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Neutral
Level
--
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Stock Forecast FAQ
In the current month, VKTX has received 9 Buy ratings 1 Hold ratings, and 0 Sell ratings. The VKTX average analyst price target in the past 3 months is $99.29.
-
Where Will Viking Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Viking Therapeutics share price will rise to $99.29 per share over the next 12 months.
-
What Do Analysts Say About Viking Therapeutics?
Analysts are divided on their view about Viking Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Viking Therapeutics is a Sell and believe this share price will drop from its current level to $38.00.
-
What Is Viking Therapeutics's Price Target?
The price target for Viking Therapeutics over the next 1-year time period is forecast to be $99.29 according to 10 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is VKTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Viking Therapeutics is a Buy. 9 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VKTX?
You can purchase shares of Viking Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Viking Therapeutics shares.
-
What Is The Viking Therapeutics Share Price Today?
Viking Therapeutics was last trading at $29.55 per share. This represents the most recent stock quote for Viking Therapeutics. Yesterday, Viking Therapeutics closed at $26.52 per share.
-
How To Buy Viking Therapeutics Stock Online?
In order to purchase Viking Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Does Intel Stock Have Room to Grow?
Intel Corporation (NASDAQ:INTC)’s recent innovations, Xeon 6 SoC and Xeon®…
Is Walmart the Largest Retailer in the World?
For many years, Walmart (NYSE:WMT) has been the world’s largest…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
44
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
45
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
50
GH alert for Mar 12
Guardant Health [GH] is up 1.1% over the past day.
Sell
44
TER alert for Mar 12
Teradyne [TER] is down 0.36% over the past day.
Buy
57
LMB alert for Mar 12
Limbach Holdings [LMB] is down 4.39% over the past day.
